

## Selective Synthesis of the Human Drug Metabolite 5'-Hydroxypropranolol by an Evolved Self-Sufficient Peroxygenase

Gomez De Santos, Patricia; Cañellas, Marina; Tieves, Florian; Younes, Sabry H.H.; Molina-Espeja, Patricia; Hofrichter, Martin; Hollmann, Frank; Guallar, Victor; Alcalde, Miguel

**DOI**

[10.1021/acscatal.8b01004](https://doi.org/10.1021/acscatal.8b01004)

**Publication date**

2018

**Document Version**

Final published version

**Published in**

ACS Catalysis

**Citation (APA)**

Gomez De Santos, P., Cañellas, M., Tieves, F., Younes, S. H. H., Molina-Espeja, P., Hofrichter, M., Hollmann, F., Guallar, V., & Alcalde, M. (2018). Selective Synthesis of the Human Drug Metabolite 5'-Hydroxypropranolol by an Evolved Self-Sufficient Peroxygenase. *ACS Catalysis*, 8(6), 4789-4799. <https://doi.org/10.1021/acscatal.8b01004>

**Important note**

To cite this publication, please use the final published version (if applicable).  
Please check the document version above.

**Copyright**

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

**Takedown policy**

Please contact us and provide details if you believe this document breaches copyrights.  
We will remove access to the work immediately and investigate your claim.



# Selective Synthesis of the Human Drug Metabolite 5'-Hydroxypropranolol by an Evolved Self-Sufficient Peroxygenase

Patricia Gomez de Santos,<sup>†</sup> Marina Cañellas,<sup>‡</sup> Florian Tieves,<sup>§</sup> Sabry H. H. Younes,<sup>§</sup> Patricia Molina-Espeja,<sup>†</sup> Martin Hofrichter,<sup>||</sup> Frank Hollmann,<sup>§</sup> Victor Guallar,<sup>‡</sup> and Miguel Alcalde<sup>\*,†</sup>

<sup>†</sup>Department of Biocatalysis, Institute of Catalysis, CSIC, 28049 Madrid, Spain

<sup>‡</sup>Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona Supercomputing Center, 08034 Barcelona, Spain


<sup>§</sup>Department of Biotechnology, Delft University of Technology, van der Massweg 9, 2629HZ Delft, The Netherlands

<sup>||</sup>Department of Bio- and Environmental Sciences, TU Dresden, International Institute Zittau, Mark 23, 02763 Zittau, Germany

## Supporting Information

**ABSTRACT:** Propranolol is a widely used beta-blocker that is metabolized by human liver P450 monooxygenases into equipotent hydroxylated human drug metabolites (HDMs). It is paramount for the pharmaceutical industry to evaluate the toxicity and activity of these metabolites, but unfortunately, their synthesis has hitherto involved the use of severe conditions, with poor reaction yields and unwanted by-products. Unspecific peroxygenases (UPOs) catalyze the selective oxyfunctionalization of C–H bonds, and they are of particular interest in synthetic organic chemistry. Here, we describe the engineering of UPO from *Agrocye aegerita* for the efficient synthesis of 5'-hydroxypropranolol (5'-OHP). We employed a structure-guided evolution approach combined with computational analysis, with the aim of avoiding unwanted phenoxyl radical coupling without having to dope the reaction with radical scavengers. The evolved biocatalyst showed a catalytic efficiency enhanced by 2 orders of magnitude and 99% regioselectivity for the synthesis of 5'-OHP. When the UPO mutant was combined with an H<sub>2</sub>O<sub>2</sub> in situ generation system using methanol as sacrificial electron donor, total turnover numbers of up to 264 000 were achieved, offering a cost-effective and readily scalable method to rapidly prepare 5'-OHP.

**KEYWORDS:** unspecific peroxygenase, human drug metabolites, 5'-hydroxypropranolol, directed evolution, peroxygenative activity, peroxidative activity, in situ H<sub>2</sub>O<sub>2</sub> generation system



## INTRODUCTION

New drugs are currently being designed thanks to a better understanding of the biological targets associated with different diseases. As such, modern organic chemistry is becoming more and more involved in the discovery and testing of new bioactive compounds.<sup>1</sup> The human liver is in charge of the metabolism of most drugs, principally through the catalytic action of cytochrome P450-monooxygenases (P450s). Their activities are responsible for the release of human drug metabolites (HDMs), which may be biologically active through different pharmacological, toxicological, or physiological interactions. Thus, it is important to be capable of synthesizing HDMs in order to perform adequate drug bioavailability, pharmacodynamics, and pharmacokinetics studies.<sup>2,3</sup> Indeed, the U.S. Food and Drug Administration (FDA) guidelines for metabolites in safety testing (MIST) declare that all metabolites generated at >10% of the total parent drug-related exposure must be subjected to safety testing.<sup>4</sup> Among the most important HDMs are those derived from propranolol (1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol), a  $\beta$ -blocker widely used to treat high blood pressure, to control heart rhythm, or to

prevent migraines.<sup>5</sup> The two main hydroxylated metabolites of propranolol are 5'-hydroxypropranolol (5'-OHP) and 4'-hydroxypropranolol (4'-OHP) which have equipotent  $\beta$ -receptor antagonist activity compared to that of propranolol.<sup>6</sup> However, their chemical synthesis is associated with poor reaction yields, an excessive number of steps and it requires high-energy input and harsh conditions, limiting their utility.<sup>7,8</sup>


The use of enzymes to hydroxylate propranolol has been studied, such as human P450s isolated from hepatic microsomes or produced in heterologous hosts, yet the constraints on expression, instability, and the low reaction rates are still serious obstacles that must be overcome.<sup>9</sup> Human P450s are membrane bound and cofactor dependent biocatalysts, such that a simpler and more autonomous system would be desirable. Accordingly, soluble bacterial P450-BM3 was engineered to work via the "peroxide shunt" pathway, i.e., fueled by catalytic amounts of H<sub>2</sub>O<sub>2</sub> in the absence of redox

Received: March 13, 2018

Revised: April 19, 2018

Published: April 19, 2018



Scheme 1. Transformation of Propranolol by UPO in the Presence of Ascorbic Acid as a Radical Scavenger<sup>a</sup>

<sup>a</sup>Peroxygenase activity converts propranolol (1) into 5'-OHP (2), a substrate of the peroxidative activity of the enzyme that leads to the formation of phenoxyl radicals (3), which can in turn undergo nonenzymatic coupling and polymerization. The inclusion of ascorbic acid (4) in the reaction mixture can alleviate the formation of unwanted side-products by reducing the conversion of (3) to (2) while it is oxidized into ascorbyl radical (5).


cofactors (NADPH) and auxiliary flavoproteins, just like an “artificial” peroxygenase. In addition, an ensemble of P450-peroxygenase variants was tailored to transform propranolol into a complex mixture of compounds enriched in the dealkylation product desisopropylpropranolol (DIP), along with low amounts of 4'-OHP and 5'-OHP.<sup>10</sup> These experiments pointed the way to develop a novel approach for the synthesis of HDMs using the first, “truly natural”, unspecific peroxygenase (UPO; EC 1.11.2.1), an extracellular heme-thiolate enzyme with mono(per)oxygense activity that was discovered at the beginning of this century.<sup>11,12</sup> Unlike P450s, the major product of UPO was shown to be 5'-OHP (91% regioselectivity), along with only minor amounts of DIP.<sup>13</sup> Despite this promising performance, UPOs can still not be used on an industrial scale due to the coexistence of peroxygenative (*P*; O-transferring two-electron oxidations) and peroxidative activities (*p*; one-electron oxidation reactions) in the same biocatalyst.<sup>13–15</sup> Hence, the enhancement of the *P:p* ratio is fundamental to perform C–H oxyfunctionalization with UPO, as demonstrated in recent works.<sup>16,17</sup> Indeed, the products of this peroxygenative activity on aromatics like propranolol become substrates of UPO's peroxidative activity, which ultimately leads to the formation of a complex mixture of phenoxyl radicals (including semiquinones) and their disproportionation (quinones) and coupling products. This mixture is further clouded by nonenzymatic polymerization, affecting the final yields and the purification of the target compounds.<sup>18,19</sup> Such problems might be partially circumvented by doping the reaction with expensive phenoxyl radical scavengers (e.g., ascorbic acid), although this solution is far from practical in terms of developing a cost-effective strategy (Scheme 1).

In a previous study, we described the heterologous functional expression of UPO from the agaric basidiomycete *Agrocybe aegerita* (*AaeUPO*) in different yeasts via directed evolution.<sup>20,21</sup> This evolution platform (PaDa-I, secretion mutant carrying four mutations in the signal peptide and five more in the mature protein) enabled us to perform further rounds of random mutation and screening to tailor an efficient UPO for the synthesis of 1-naphthol, notably increasing the *P:p* ratio of the final JaWa variant (containing the G241D-R257K

mutations).<sup>16</sup> In this work, we have combined computational simulations with directed evolution methods to design a UPO variant for the high-efficient, selective synthesis of 5'-OHP from propranolol in the absence of radical scavengers. We first made a benchmarking with native and evolved UPOs in the transformation of propranolol, selecting JaWa variant as the most suitable departure point for engineering. Focused mutagenesis and DNA recombination in yeast was coupled to a specific high-throughput assay for the synthesis of 5'-OHP, yielding a final variant that was characterized biochemically in depth. To bypass the oxidative inactivation suffered by UPO and maximize the total turnover numbers (TTN), an enzymatic cascade for the in situ supply of  $\text{H}_2\text{O}_2$  using methanol as sacrificial electron donor was coupled to the reaction. The effect of the *P:p* ratio during the synthesis of 5'-OHP by the evolved UPO was analyzed by ligand migration and molecular dynamics simulations aimed at obtaining an atomic explanation of the mutations involved in the catalysis.

## RESULTS AND DISCUSSION

As a starting point for the present study, we used a colorimetric screening assay based on 4-aminoantipyrine (4-AAP)<sup>22</sup> to benchmark the wildtype UPO (*AaeUPO*), PaDa-I, and JaWa mutants in the reaction with propranolol, assessing the variants in terms of their activity in the presence and absence of ascorbic acid (AA); see Figures S1–S3 in the Supporting Information. Significantly, the JaWa mutant outperformed both the *AaeUPO* and PaDa-I variants by ~4-fold (in both the presence and absence of AA; Figure S3b in the Supporting Information). Given that JaWa showed TTN of 50 000 in the transformation of naphthalene into 1-naphthol,<sup>16</sup> the structural similarities between naphthalene and propranolol, and the location of the G241D mutation at the entrance of the heme access channel, we searched for new catalytic motifs to be subjected to focused evolution. Molecular docking simulations<sup>23</sup> with propranolol underlined the possibility that, along with Phe191, the G241D mutation favored the anchoring of propranolol (Figure 1). Accordingly, we selected the D187-V248 segment for random mutagenesis and DNA recombination by MORPHING (mutagenic organized recombination process by homologous



**Figure 1.** Selected region for focused evolution. The UPO structure (JaWa mutant) is shown as a gray cartoon, and the relevant amino acids are indicated in yellow, together with the distances between them and the propanolol molecule (in green) or to the heme group (in dark red). The F191 position and G241D substitution seem to be involved in positioning the aliphatic branch of propanolol, while A77 apparently interacts with the aromatic rings and L39 lies underneath the heme. The D187-V248 segment (in pink) was subjected to MORPHING, harboring the  $\alpha$ -helix where F191 is located and the loop of G241D. Docking simulations were performed using Molecular Operating Environment (MOE) software<sup>23</sup> and the crystal structure of the evolved UPO at a resolution of 1.2 Å (provided by Prof. Julia Sanz, IQFR-CSIC, Madrid, unpublished material).


in vivo grouping),<sup>24</sup> excluding the introduction of destabilizing mutations in the remaining protein structure. We constructed two mutant libraries with different mutational loads and screened them using the 4-AAP assay (Figure S4 in the Supporting Information). As selection criterion, we imposed that UPO variants had to oxidize propanolol exceeding a threshold of 1.5-fold of parental's activity. After two consecutive rescreenings, the six selected clones that satisfied the activity threshold carried the same single substitution (F191S), which did not jeopardize thermostability as the  $T_{50}$  value for both the parental JaWa and the mutant was maintained at  $\sim 60$  °C (Figures S4 and S5 in the Supporting Information). This mutation improved the formation of 5'-OHP in the absence of AA up to 230%, and most importantly, the ratio between both reactions enhanced 1.8-fold in the presence and absence of AA. Given that Phe191 and Phe76 are responsible for defining the entrance to the heme access channel, whereas the aromatic triad formed by Phe69, Phe121, and Phe199 is involved in orienting the substrate for catalysis, all these residues were studied by saturation mutagenesis using as template the F191S variant (Figure S6 in the Supporting Information).<sup>25</sup> We first designed a combinatorial saturation mutagenesis library of Phe191 and Phe76 in which the most active clones exclusively incorporated again the F191S substitution. When individual saturation mutagenesis was performed at Phe69, Phe121, and Phe199, a set of nonfunctional libraries was obtained (80% inactive clones), with no further beneficial substitutions identified (Figure S7 in the Supporting Information).

The mutant clone containing the F191S mutation (named SoLo), JaWa, PaDa-I, and AaeUPO were all produced, purified to homogeneity [Reinheitszahl,  $R_z$  ( $A_{418}/A_{280}$ )  $\approx 2.2$ ] and characterized biochemically and computationally at the atomic level. We first analyzed the transformation of propanolol by HPLC-PDA (Figure 2c), and notably, the regioselectivity for 5'-OHP shifted from 91% in AaeUPO to 99% in PaDa-I, JaWa and SoLo. When boosting the UPO by periodic dosing with 2 mM  $H_2O_2$  over the course of the reaction, without supplying AA, TTNs of 3000, 15 000, and 45 000 were achieved for the AaeUPO, JaWa, and SoLo mutants, respectively, roughly representing a 15-fold improvement of SoLo relative to the wildtype AaeUPO (Figure 2a,b). More significantly, in the absence of AA, the SoLo mutant still outperformed the TTN of the wildtype doped with AA more than 3-fold (viz. 45 000 and 14 000 TTN for SoLo in the absence of AA and AaeUPO in the presence of AA, respectively).

Kinetic parameters were measured for the one-electron oxidation of ABTS (peroxidative activity), for the two-electron oxidation of propanolol into 5'-OHP (peroxygenative activity), and for  $H_2O_2$  with benzyl alcohol as peroxygenative substrate (Table 1). SoLo showed a striking 14-fold and 17-fold drop in the catalytic efficiency ( $k_{cat}/K_m$ ) with ABTS relative to AaeUPO and PaDa-I, respectively, while maintaining similar performance as JaWa. The strong enhancement in the  $K_m$ , with a maximal 23-fold increase relative to AaeUPO was mostly responsible for this effect. Kinetic differences for propanolol were even more dramatic and the catalytic efficiencies for JaWa and SoLo were 2 orders of magnitude higher than for AaeUPO and PaDa-I, mostly due to the important 5- to 10-fold decrease in the  $K_m$  for this substrate. The kinetics for  $H_2O_2$  in the peroxygenation of benzyl alcohol did not differ among the UPO variants.

In order to study the differences found between the AaeUPO, PaDa-I, JaWa, and SoLo variants during propanolol hydroxylation at the atomic level, we turned to molecular modeling employing PELE (Protein Energy Landscape Exploration), a Monte Carlo algorithm capable of effectively sampling the protein–ligand conformational space.<sup>26</sup> We first modeled propanolol diffusion to the active site for each variant, finding that binding energies and distances largely correlate with the experimental  $K_m$  (Figure 3 and Supporting Movie). To facilitate oxygenation, ideally the distances between the  $C_5$  propanolol carbon atom and the catalytic heme-ferryl oxygen should be around (or below) 4 Å. JaWa, with the lowest  $K_m$  for propanolol, clearly presents the best “catalytic minimum”, with a distance around 3.5 Å and a binding energy at ca.  $-70$  kcal/mol. On the other hand, AaeUPO and PaDa-I, with noticeably higher  $K_m$ , have markedly worse binding energy profiles, which would result in the necessity of adding more substrate to reach correct catalytic positions. Moreover, when we analyzed the relative distance distribution of substrate's  $C_5$  atom in the active site (Figure 3), we obtained a similar tendency: the relative frequency of structures below 4 Å is significantly higher for JaWa and SoLo variants. In addition, simulations provided important insights into the influence of the G241D mutation present in both JaWa and SoLo but absent in AaeUPO and PaDa-I (Supporting Movie), which facilitates the anchoring of the substrate in a more favorable orientation for hydroxylation. Besides, the Phe191 residue seems to tighten the stabilization of this catalytic orientation in the JaWa variant which is in agreement with the slight kinetic differences between both variants for propanolol. To obtain further structural insights into the changes caused by F191S mutation, 100 ns molecular





**Figure 2.** Propranolol conversion by native and mutant UPOs. (A and B) Time course of the reactions over 120 min at pH 7.0 with the wildtype *AaeUPO* and the *SoLo* mutant, respectively. White circles, propranolol (with AA); black circles, propranolol (without AA); white squares, 5'-OHP (with AA); black squares, propranolol (without AA); arrows, periodic pulses of 2 mM H<sub>2</sub>O<sub>2</sub>. The total turnover numbers (TTN,  $\mu\text{mol product}/\mu\text{mol enzyme}$ ) were estimated from the 5'-OHP concentration after 120 min. (C) The HPLC elution profiles after a reaction time of 60 min in the absence of AA: 1, *SoLo*; 2, *JaWa*; 3, *PaDa-I*; 4, *AaeUPO*; 5, control without enzyme; and \*, traces of DIP. (D) Conversion of 5'-OHP into phenoxyl radicals and polymers. Reaction conditions can be found in the [Materials and Methods](#) section.


**Table 1. Steady Kinetic Parameters of UPO Variants**

substrate	kinetic constant	<i>AaeUPO</i>	<i>PaDa-I</i>	<i>JaWa</i>	<i>SoLo</i>
ABTS	$K_m$ ( $\mu\text{M}$ )	$25 \pm 2$	$50 \pm 6$	$181 \pm 22$	$568 \pm 91$
	$k_{\text{cat}}$ ( $\text{s}^{-1}$ )	$221 \pm 6$	$546 \pm 19$	$125 \pm 5$	$365 \pm 23$
	$k_{\text{cat}}/K_m$ ( $\text{M}^{-1} \text{s}^{-1}$ )	$8.8 \times 10^6 \pm 6.9 \times 10^5$	$11.0 \times 10^6 \pm 6.0 \times 10^5$	$6.9 \times 10^5 \pm 6.3 \times 10^4$	$6.4 \times 10^5 \pm 6.7 \times 10^4$
propranolol	$K_m$ ( $\mu\text{M}$ )	$2239 \pm 333$	$2268 \pm 220$	$244 \pm 92$	$391 \pm 97$
	$k_{\text{cat}}$ ( $\text{s}^{-1}$ )	$150 \pm 12$	$212 \pm 11$	$765 \pm 76$	$497 \pm 35$
	$k_{\text{cat}}/K_m$ ( $\text{M}^{-1} \text{s}^{-1}$ )	$6.7 \times 10^4 \pm 4.8 \times 10^3$	$9.3 \times 10^4 \pm 4.3 \times 10^3$	$3.1 \times 10^6 \pm 0.9 \times 10^5$	$1.3 \times 10^6 \pm 0.2 \times 10^5$
H <sub>2</sub> O <sub>2</sub>	$K_m$ ( $\mu\text{M}$ )	$1370 \pm 162$	$1530 \pm 80$	$1250 \pm 300$	$1430 \pm 153$
	$k_{\text{cat}}$ ( $\text{s}^{-1}$ )	$290 \pm 15$	$676 \pm 24$	$447 \pm 40$	$446 \pm 23$
	$k_{\text{cat}}/K_m$ ( $\text{M}^{-1} \text{s}^{-1}$ )	$2.1 \times 10^5 \pm 1.5 \times 10^4$	$4.4 \times 10^5 \pm 12.0 \times 10^4$	$3.6 \times 10^5 \pm 5.9 \times 10^4$	$3.1 \times 10^5 \pm 1.8 \times 10^4$

dynamics (MD) were performed with *JaWa* and *SoLo*. MD pocket method<sup>27</sup> was used to track heme's cavity volume changes along the MD trajectories, showing a widening of the *SoLo* variant pocket compared to *JaWa* of  $\sim 50 \text{ \AA}^3$  (Figure 4C–E). The most obvious reason behind the cavity broadening is the mutation Phe191 to a less bulky amino acid such as serine. Moreover, structure visual inspection in *JaWa* shows that Phe191 tends to be placed in the hydrophobic heme cavity, causing a displacement of the  $\alpha$ -helix hosting it and reducing the heme pocket volume. In the *SoLo* variant, such movement does not occur since Ser191 is kept buried into the protein by a


hydrogen bond interaction within its hosting  $\alpha$ -helix (Figure 4A,B).

However, we still wanted to ascertain why there was more 5'-OHP formed by *SoLo* than by *JaWa*, particularly given that the latter had an even higher catalytic efficiency for propranolol (Table 1). We hypothesized that the F191S mutation, which widens the access channel (Figure 4), could play an important role in bypassing the unwanted peroxidative activity on 5'-OHP (2) and the ensuing formation of the phenoxyl radical (3), thereby increasing the *P:p* ratio (numbering according to Scheme 1). To unveil the weaker peroxidative activity of *SoLo*, we measured the disappearance of 2 by HPLC-PDA during the



**Figure 3.** Computational analysis of propranolol diffusion in native and mutant UPOs. Interaction energies (in  $\text{kcal}\cdot\text{mol}^{-1}$ ) vs. ligand distances (in Å) from PELE simulations with propranolol in AaeUPO, PaDa-I, JaWa, and SoLo UPO variants. The distances are between the reactive O atom in the heme compound I and the  $\text{C}_5$  atom of propranolol. The top-right (inset) plots show the relative population for all of the structures with interaction energies below  $-50\text{ kcal}\cdot\text{mol}^{-1}$  using binning widths of  $0.5\text{ Å}$ .

### Scheme 2. Enzymatic Cascade for in Situ $\text{H}_2\text{O}_2$ Generation<sup>a</sup>




<sup>a</sup>Alcohol oxidase (AOx) and formaldehyde dismutase (FDM) perform the double oxidation of methanol to formic acid for the generation of two equivalents of  $\text{H}_2\text{O}_2$ <sup>28</sup> which are used by the UPO mutant (SoLo) for the formation of 5'-OHP.

reaction with the different variants in the absence of AA (4), using 2 as the departure reducing substrate. Pleasingly, the rate of converting 2 into 3 was noteworthy for all of the variants except SoLo, which maintained a concentration of the substrate 10-fold higher than that of the rest of the variants after 10 min of the reaction (Figure 2d). These noticeable differences became readily visible because the polymeric products formed through the nonenzymatic coupling of the phenoxyl radicals are colored (see inset in Figure 2d). These results were confirmed computationally by PELE whereby the 5'-OHP diffusion addressed the significantly smaller concentration of this

peroxidative substrate at lower distances ( $<5\text{ Å}$ ) from the heme catalytic center in SoLo compared to JaWa, as well as shorter residence times in the binding site (Figure S8 in the Supporting Information) which results in the inefficient 5'-OHP oxidation by SoLo variant. Taken together, our results unequivocally show that, while the F191S mutation acts as the main driver of the remarkable decrease in peroxidative activity on 2, the G241D change is mostly responsible for the improved peroxygenative activity on 1 (Figure S9 in the Supporting Information).

To address the well-known lability of heme-containing enzymes (including UPOs) against  $\text{H}_2\text{O}_2$ , we evaluated two strategies using either in situ generation of  $\text{H}_2\text{O}_2$  from ambient  $\text{O}_2$ <sup>28</sup> or using *tert*-butyl hydroperoxide (*tert*-BuOOH) as milder peroxide source.<sup>29</sup> For in situ  $\text{H}_2\text{O}_2$  generation we utilized a bienzymatic cascade comprising alcohol oxidase (AOx) and formaldehyde dismutase (FDM) for the double oxidation of methanol to formic acid (generating two equivalents of  $\text{H}_2\text{O}_2$ , Scheme 2).<sup>28</sup> With such a system, TTNs as high as 264 000 and 226 000 were achieved with and without AA, respectively. Also the second strategy, i.e., using *tert*-BuOOH as a milder oxidant, proved successful (Figure S10 in the Supporting Information). On a semipreparative scale, 20 and 10 mM of 5'-OHP were produced (20 and 40% analytical yield, respectively) with and without AA, respectively. The final product was isolated and further purified via a one-step flash chromatography step yielding 10.5 mg of pure 5'-OHP (as confirmed by  $^1\text{H}$  NMR,



**Figure 4.** F191S induced structural changes along 100 ns MD. (A and B) JaWa and SoLo (colored in green and dark blue, respectively) comparison at the beginning (0 ns, panel A) and at the end (100 ns, panel B) of the MD simulation. Simulations show that, while the F191 residue in JaWa causes a displacement of the  $\alpha$ -helix hosting it and leads to the reduction of the heme cavity, in the SoLo variant F191S avoids the heme pocket hydrophobicity and tends to be buried into the  $\alpha$ -helix holding it, interacting mainly with nearby residues (a hydrogen bond with D187 is conserved 87% among the MD). (C) Heme cavity volume tracking along 100 ns MD simulations for JaWa and SoLo variants, calculated with MDpocket every 0.1 ns. Smoothed volume of the pocket is shown in thick lines. (D and E) Heme binding pocket volume representation as a mesh surface for JaWa (panel D) and SoLo (panel E) variants after 100 ns MD simulation.

Figure S11 in the [Supporting Information](#)) in overall 15.2% isolated yield. It should, however, be emphasized that neither the synthetic reaction nor the isolation and purification procedure were optimized.

## CONCLUSIONS AND OUTLOOK

By using  $\text{H}_2\text{O}_2$  as a final electron acceptor and exclusive oxygen donor, UPO carries out a variety of oxygen-transfer reactions, and as such, it is considered by many to be “taking the baton” from P450s in the field of synthetic organic chemistry.<sup>19,29–31</sup> In this study, we designed a highly active and stable UPO variant that behaves as a self-sufficient and efficient biocatalyst for the selective synthesis of 5'-OHP, irrespective of the

presence of radical scavengers in the reaction. The UPO mutant shows the highest regioselectivity and TTN for the synthesis of 5'-OHP reported so far. When we compare it with the best engineered P450 BM3 heme domain peroxidase, the SoLo mutant surpasses it roughly by 9000-fold.<sup>10–14</sup> More significantly, with the assistance of a  $\text{H}_2\text{O}_2$  in situ generation system based on an enzyme cascade reaction with methanol as the sacrificial electron donor for the reductive activation of  $\text{O}_2$ ,<sup>28</sup> this UPO variant outperforms any natural or engineered hydroxylating catalyst described to date going one step closer to the industrial needs.<sup>32</sup>







**High Throughput Dual screening:** Individual clones were picked and inoculated in sterile 96-well plates (Greiner Bio-One, GmbH, Germany), referred to as master plates, containing 200  $\mu\text{L}$  of SEM per well. In each plate, column number 6 was inoculated with the parent type, and one well (H1-control) was inoculated with *S. cerevisiae* transformed with pJRoC30-MtL plasmid (laccase without activity). Plates were sealed with parafilm to prevent evaporation and incubated at 30  $^{\circ}\text{C}$ , 220 rpm and 80% relative humidity in a humidity shaker (Minitron, Infors, Switzerland) for 5 days. The master plates were centrifuged (Eppendorf 5810R centrifuge, Germany) for 10 min at 2500g and 4  $^{\circ}\text{C}$ . Aliquots of the supernatants (20  $\mu\text{L}$ ) were transferred from the master plates to two replica plates with the aid of a liquid handler robotic station Freedom EVO (Tecan, Switzerland). A total of 50  $\mu\text{L}$  of the reaction mixture (with or without ascorbic acid) was added to the two replica plates with the help of a pipetting robot (Multidrop Combi Reagent Dispenser, Thermo Scientific, MA, U.S.A.). The reaction mixture for replica plate 1 contained 50 mM potassium phosphate buffer (pH 7.0), 5 mM propranolol, and 2 mM  $\text{H}_2\text{O}_2$ . The reaction mixture for replica plate 2 contained 50 mM potassium phosphate buffer (pH 7.0), 5 mM propranolol, 2 mM  $\text{H}_2\text{O}_2$ , and 4 mM ascorbic acid. Replica plates 1 and 2 were incubated at room temperature for 30 and 60 min, respectively. Afterward, the amount of 5'-OHP formed in each well was determined by the 4-aminoantipyrine (4-AAP) assay<sup>22</sup> (Figures S1–S3 in the Supporting Information). Plates were stirred briefly, and absorption at 530 nm was recorded in a plate reader (SPECTRAMax Plus 384, Molecular Devices, U.S.A.). The values were normalized against the parent type of the corresponding plate, and selected variants came from the ratio between the values obtained in the absence (peroxygenative +peroxidative activities) and in the presence (peroxygenative activity) of ascorbic acid. To rule out the selection of false positives, two rescreenings were carried out as described elsewhere.<sup>20</sup>

**Production, Purification, and Biochemical Characterization.** AaeUPO wildtype and recombinant UPO (PaDa-I, JaWa, and SoLo variants) were produced and purified as described before with minor modifications.<sup>11,16,20</sup> Recombinant UPO purification was achieved by cationic exchange chromatography and anion exchange chromatography (AKTA purifier, GE Healthcare, WI, U.S.A.). The crude extract was concentrated and dialyzed in sodium phosphate/citrate 20 mM at pH 3.3 (buffer A) by tangential ultrafiltration (Pellicon; Millipore, Temecula, CA, U.S.A.) through a 10-kDa-pore-size membrane (Millipore) by means of a peristaltic pump (Masterflex Easy Load; Cole-Parmer, Vernon Hills, IL, U.S.A.). The sample was filtered and loaded onto a strong cation-exchange column (HiTrap SP FF GE Healthcare) pre-equilibrated with buffer A. The proteins were eluted with a linear gradient from 0 to 40% of buffer A within 60 mL of NaCl and from 40 to 100% within 5 mL at a flow rate of 1 mL/min. Fractions with UPO activity vs ABTS were harvested, concentrated, dialyzed against buffer Tris HCl 20 mM at pH 7.8 (buffer B), and loaded onto a 10  $\mu\text{m}$  high resolution anion-exchange Biosuite Q column (Waters) pre-equilibrated with buffer B. The proteins were eluted with a linear gradient from 0 to 20% within 40 mL of NaCl and from 20 to 100% within 5 mL at a flow rate of 1 mL/min. The fractions with UPO activity vs. ABTS were pooled, dialyzed against buffer potassium phosphate 10 mM at pH 7.0 and stored at 4  $^{\circ}\text{C}$ .

**Steady-state kinetic constants:** ABTS kinetics were measured in sodium phosphate/citrate buffer (pH 4.0, 100 mM), containing  $\text{H}_2\text{O}_2$  (2 mM) and for propranolol in potassium phosphate buffer (pH 7.0, 50 mM) containing  $\text{H}_2\text{O}_2$  (2 mM). For  $\text{H}_2\text{O}_2$ , benzyl alcohol was used as a reducing substrate under the corresponding saturated conditions. Reactions were performed in triplicate, and substrate oxidations were followed through spectrophotometric changes ( $\epsilon_{418}\text{ABTS}^{*+} = 36\,000\text{ M}^{-1}\text{ cm}^{-1}$ ;  $\epsilon_{325}\text{ 5'-OHP} = 1996\text{ M}^{-1}\text{ cm}^{-1}$ , and  $\epsilon_{280}\text{ benzaldehyde} = 1400\text{ M}^{-1}\text{ cm}^{-1}$ ).

**HPLC analysis:** The reaction mixtures were analyzed by reversed-phase chromatography (HPLC) with equipment consisting of a tertiary pump (Varian/Agilent Technologies) coupled to an autosampler (Merck Millipore) and an Zorbax Eclipse plus C18 (15 cm  $\times$  4,6 cm) column at 40  $^{\circ}\text{C}$ . Detection was performed with a PDA (Varian/Agilent Technologies). The mobile phase was a gradient from 10% methanol and 90% ddH<sub>2</sub>O (both with 0.1% acetic acid) to 90% methanol and 10% ddH<sub>2</sub>O at a flow rate of 0.8 mL/min. The reaction was quantified at 280 nm (from HPLC standards). Reaction mixtures contained 0.03  $\mu\text{M}$  purified enzyme, 5 mM propranolol, and 2 mM  $\text{H}_2\text{O}_2$  in 50 mM potassium phosphate pH 7.0 (0.5 mL final volume). After 60 min at room temperature, the reaction was stopped by heating 10 min at 70  $^{\circ}\text{C}$  and cooling 5 min at 4  $^{\circ}\text{C}$  (see Figure 2C). Total turnover numbers were calculated from the reaction that contained 0.03  $\mu\text{M}$  purified enzyme, 5 mM propranolol, and pulses of 2 mM  $\text{H}_2\text{O}_2$  every 10 min in 50 mM potassium phosphate buffer pH 7.0 (0.5 mL final volume). Reactions were stopped at different times (10–120 min) as described before (see Figure 2A,B). In the determination of 5'-hydroxypropranolol (5'-OHP) consumption by UPO, the mixture contained 0.03  $\mu\text{M}$  purified enzyme, 0.5 mM 5'-OHP, 20% methanol 20% and 2 mM  $\text{H}_2\text{O}_2$  in 50 mM potassium phosphate buffer pH 7.0 (0.5 mL final volume). The reaction was started by the addition of the  $\text{H}_2\text{O}_2$  and stopped at different times (2–10 min) as described before (see Figure 2D). Samples of each experiment (20  $\mu\text{L}$ ) were injected and analyzed. Standard deviations were lower than 5% in all experiments. Products were identified and quantified against authentic standards by the HPLC method mentioned above.

**Kinetic thermostability:** The thermostability of the different UPO samples was estimated by assessing their  $T_{50}$  values using 96/384 well gradient thermocyclers. Appropriate UPO dilutions were prepared with the help of the robot in such a way that 20  $\mu\text{L}$  aliquots gave rise to a linear response in the kinetic mode. Then, 50  $\mu\text{L}$  were used for each point in the gradient scale, and a temperature gradient profile ranging from 30 to 80  $^{\circ}\text{C}$  was established as follows (in  $^{\circ}\text{C}$ ): 30.0, 31.7, 34.8, 39.3, 45.3, 49.9, 53.0, 55.0, 56.8, 59.9, 64.3, 70.3, 75.0, 78.1, and 80.0. After a 10 min incubation, samples were chilled on ice for 10 min and further incubated at room temperature for 5 min. Afterward, 20  $\mu\text{L}$  of samples were subjected to the ABTS colorimetric assay described elsewhere.<sup>20</sup> The thermostability values were deduced from the ratio between the residual activities incubated at different temperature points and the initial activity at room temperature.

**Reaction Optimization and Product Identification.** Production of 5'-OHP by SoLo coupled to an in situ  $\text{H}_2\text{O}_2$  generation system: For in situ  $\text{H}_2\text{O}_2$  generation, 10 nM SoLo mutant, 10 nM alcohol oxidase from *Pichia pastoris* (AOx), and 600 nM formate dismutase from *Pseudomonas putida* (FDM) in combination with 200 mM methanol were used.<sup>28</sup> Reactions

were performed at 30 °C and 600 rpm in 100 mM potassium phosphate buffer pH 7.0 with 10 mM of propranolol in a total volume of 375  $\mu$ L using a thermo shaker device (Eppendorf, Germany). After 3 h, the reactions were stopped by heat inactivation for 10 min at 70 °C, followed by cooling the sample and separation of precipitate by centrifugation at 5 °C. Quantification of 5'-OHP was carried out by HPLC analytics. HPLC measurements were performed at 40 °C on a Shimadzu LC-20 system with a Shimadzu SPD-M20A Photo Diode Array detector using Waters Xterra RP18 column (4.6  $\times$  150 mm, 3.5  $\mu$ m). For the mobile phase, acetonitrile (ACN) and water containing 5% ACN and 0.1% trifluoroacetic acid (TFA) were used. The separation was performed in an isocratic mode at a flow rate of 1.0 mL/min while increasing the ACN concentration in three steps to finally 100%: 25%, 4 min hold; 50%, 4 min hold; and 100%, 3 min hold. The reaction was quantified at 280 nm based on a calibration using 5'-OHP standard.

**Semipreparative production of 5'-OHP:** For the semipreparative production of 5'-OHP, 50 mM propranolol was dissolved in 100 mM potassium phosphate buffer pH 7.0 (10 mL total volume). Reactions were performed at 30 °C while gently mixing (neoLab rotator, mode C2, 20 rpm, Germany) in presence or absence of 40 mM of AA using 0.5  $\mu$ M of SoLo. The reaction was started by the addition of 5 mM *tert*-butyl hydroperoxide (*tert*-BuOOH). Every hour, 5 mM *tert*-BuOOH was added and 200  $\mu$ L of each reaction time were taken for 5'-OHP quantification by HPLC. After 9 h, 5 mL of the reaction mixture was used for 5'-OHP isolation. The solution was acidified (200  $\mu$ L, 37% HCl), extracted with ethyl acetate (3  $\times$  5 mL), and dried with MgSO<sub>4</sub>, and the solvent was removed under reduced pressure. The crude product was purified by column chromatography using silica gel (60 Å, 230–400 mesh) with a dichloromethane (DCM)/methanol eluent (8:2). Separation follow, using thin layer chromatography (TLC) on silica gel-coated plates (Macherey-Nagel, Polygram SIL G/UV254) with a DCM/methanol solvent mixture (9:1).

**NMR analytics:** NMR spectra were recorded on an Agilent 400 (400 MHz) spectrometer in methanol-*d*<sub>4</sub>. Chemical shifts are given in ppm with respect to tetramethylsilane. Coupling constants are reported as *J* values in Hz (Figure S11 in the Supporting Information).

**Computational Analysis.** System preparation for molecular modeling: The starting structure for PELE (Protein Energy Landscape Exploration) simulations with *Aae*UPO was the *Agroclybe aegerita* peroxygenase crystal structure (PDB ID: 2YOR). For the different UPO mutants, the crystal structure of PaDa-I (at a resolution of 1.5 Å, courtesy of Prof. Julia Sanz, IQFR-CSIC, Madrid, unpublished material) was used for modeling. Since the optimal pH for propranolol peroxygenation and subsequent 5'-OHP peroxidation is 7.0, all of the structures were prepared accordingly with the aid of the Schrödinger Protein Preparation Wizard<sup>35</sup> and the H++ web server.<sup>36</sup> All acidic residues were deprotonated. Histidines were  $\delta$ -protonated, with the exception of His82 ( $\epsilon$ -protonated) and His118 and His251 (double-protonated). To relax the systems after mutations insertion and to investigate their possible effect on the protein structure, 5 ns of Molecular Dynamics simulation (MD) were performed with Desmond<sup>37</sup> on the JaWa and SoLo structures. Finally, the heme site was modeled as compound I after being fully optimized in the protein environment with quantum mechanics/molecular mechanics (QM/MM) using QSite.<sup>38</sup> Propranolol and 5'-OHP molecules

were also optimized with Jaguar<sup>39</sup> at the DFT/M06 level with the 6-31G\*\* basis and PBF implicit solvent in order to obtain their electrostatic potential atomic charges.

**Protein energy landscape exploration (PELE) computational analysis:** Once all protein and ligand structures were prepared, heme binding site explorations were performed with PELE.<sup>26</sup> Substrates were manually placed in identical positions at the entrance of the heme-access channel, and PELE simulations were carried out in two different stages. First, ligands were driven from the solvent to the UPO heme binding site. Then, once the center of mass of the ligand was within 6 Å of the heme catalytic oxygen, it was free to explore the active site. The results presented here are based on 160 independent 48 h PELE simulations. Moreover, in an attempt to increase the sampling for 5'-OHP diffusion, additional PELE simulations were performed for this substrate. Representative structures at distances lower than 10 Å (considering the distance between the reactive O-heme atom and the H<sub>5</sub> substrate atom) were selected using binning widths of 1 Å from previous PELE simulations and used as starting structures for the new ones. New simulations were set up to freely explore the active site, and a total of 196 independent 48 h simulations were run.

**Molecular Dynamics and MDpocket:** To study the changes caused by F191S mutation, 100 ns MD simulations were performed with JaWa and SoLo using Desmond.<sup>37</sup> To prepare the system for MD, previously mentioned prepared JaWa and SoLo systems were placed inside an orthorhombic box containing SPC explicit waters and ions to neutralize the system at a concentration of 0.15 M NaCl. From the solvated system, MD simulations were run with the following parameters: the OPLS-2005 force field, the temperature was regulated with a Nose-Hoover chain thermostat with a relaxation time of 1.0 ps, the pressure with the Martyna–Tobias–Klein barostat with isotropic coupling and a relaxation time of 2.0 ps, and finally, the production phase was run over the course of 100 ns using the NPT canonical ensemble at 300 K. From MD simulations, structures at every 0.1 ns were extracted and used for volume pocket calculation with MDpocket,<sup>27</sup> a fast and open-source tool for protein pocket (cavity) detection on molecular dynamic trajectories or other conformational ensembles.

## ■ ASSOCIATED CONTENT

### ● Supporting Information

This material is available free of charge on the ACS Publications Web site. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acscatal.8b01004.

Additional material pertaining to experimental results (Figures S1–S11) (PDF)

Movie showing diffusion and binding site positioning of propranolol in *Aae*UPO and SoLo mutant (AVI)

## ■ AUTHOR INFORMATION

### Corresponding Author

\*E-mail: malcalde@icp.csic.es.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

We thank Francisco J. Plou and Paloma Santos Moriano for assistance with the HPLC-PDA analysis (ICP, CSIC, Spain).

This work was supported by the European Union Project H2020-BBI-PPP-2015-2-720297-ENZOX2 and the COST Action CM1303 Systems Biocatalysis, the Spanish Government Projects BIO2016-79106-R-Lignolution and CTQ2016-70138-R, and the CSIC Project PIE-201580E042.

## REFERENCES

- (1) National Research Council *Industrialization of Biology: A Roadmap to Accelerate the Advanced Manufacturing of Chemicals*; The National Academies Press: Washington, DC, 2015.
- (2) Baillie, T. A.; Cayen, M. N.; Fouda, H.; Gerson, R. J.; Green, J. D.; Grossman, S. J.; Klunk, L. J.; LeBlanc, B.; Perkins, D. G.; Shipley, L. A. Drug metabolites in safety testing. *Toxicol. Appl. Pharmacol.* **2002**, *182*, 188–196.
- (3) Atrakchi, A. H. Interpretation and considerations on the safety evaluation of human drug metabolites. *Chem. Res. Toxicol.* **2009**, *22*, 1217–1220.
- (4) Guengerich, F. P. Safety Assessment of Stable Drug Metabolites. *Chem. Res. Toxicol.* **2009**, *22*, 237–238.
- (5) Al-Majed, A. A.; Bakheit, A. H. H.; Abdel Aziz, H. A.; Alajmi, F. M.; AlRabiah, H. Propranolol. In *Profiles of Drug Substances, Excipients and Related Methodology*; Brittain, H. G., Ed.; Elsevier: United Kingdom, 2017; Vol. 42, pp 287–338.
- (6) Greenslade, F. C.; Newquist, K. L. In vitro measurement of the beta-adrenergic blocking properties of ORF 12592, the 5-hydroxy analog of propranolol. *Arch. Int. Pharmacodyn. Ther.* **1978**, *233*, 270–280.
- (7) Oatis, J. E., Jr; Russell, M. P.; Knapp, D. R.; Walle, T. Ring-Hydroxylated Propranolol: Synthesis and P-Receptor Antagonist and Vasodilating Activities of the Seven Isomers. *J. Med. Chem.* **1981**, *24*, 309–314.
- (8) Kumamoto, T.; Aoyama, N.; Nakano, S.; Ishikawa, T.; Narimatsu, S. Synthesis of enantiomeric 4-hydroxypropranolols from 1,4-dihydroxynaphthalene. *Tetrahedron: Asymmetry* **2001**, *12*, 791–795.
- (9) Eiben, S.; Kayser, L.; Maurer, S.; Kühnel, K.; Urlacher, V. B.; Schmid, R. D. Preparative use of isolated CYP102 monooxygenases – a critical appraisal. *J. Biotechnol.* **2006**, *124*, 662–669.
- (10) Otey, C. R.; Bandara, G.; Lalonde, J.; Takahashi, K.; Arnold, F. H. Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. *Biotechnol. Bioeng.* **2006**, *93*, 494–499.
- (11) Ullrich, R.; Nüske, J.; Scheibner, K.; Spantzel, J.; Hofrichter, M. Novel haloperoxidase from the agaric basidiomycete *Agrocybe aegerita* oxidizes aryl alcohols and aldehydes. *Appl. Environ. Microbiol.* **2004**, *70*, 4575–4581.
- (12) Hofrichter, M.; Ullrich, R. Oxidations catalyzed by fungal peroxxygenases. *Curr. Opin. Chem. Biol.* **2014**, *19*, 116–125.
- (13) Poraj-Kobielska, M.; Kinne, M.; Ullrich, R.; Scheibner, K.; Kayser, G.; Hammel, K. E.; Hofrichter, M. Preparation of human drug metabolites using fungal peroxxygenases. *Biochem. Pharmacol.* **2011**, *82*, 789–796.
- (14) Kinne, M.; Poraj-Kobielska, M.; Aranda, E.; Ullrich, R.; Hammel, K. E.; Scheibner, K.; Hofrichter, M. Regioselective preparation of 5-hydroxypropranolol and 4'-hydroxydiclofenac with a fungal peroxxygenase. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 3085–3087.
- (15) Kiebitz, J.; Holla, W.; Heidrich, J.; Poraj-Kobielska, M.; Sandvoss, M.; Simonis, R.; Gröbe, G.; Atzrodt, J.; Hofrichter, M.; Scheibner, K. One-pot synthesis of human metabolites of SARS48304 by fungal peroxxygenases. *Bioorg. Med. Chem.* **2015**, *23*, 4324–4332.
- (16) Molina-Espeja, P.; Cañellas, M.; Plou, F. J.; Hofrichter, M.; Lucas, F.; Guallar, V.; Alcalde, M. Synthesis of 1-Naphthol by a Natural Peroxygenase Engineered by Directed Evolution. *ChemBioChem* **2016**, *17*, 341–349.
- (17) Mate, D. M.; Palomino, M. A.; Molina-Espeja, P.; Martin-Diaz, J.; Alcalde, M. Modification of the peroxxygenative:peroxidative activity ratio in the unspecific peroxxygenase from *Agrocybe aegerita* by structure-guided evolution. *Protein Eng., Des. Sel.* **2017**, *30*, 189–196.
- (18) Ullrich, R.; Hofrichter, M. Enzymatic hydroxylation of aromatic compounds. *Cell. Mol. Life Sci.* **2007**, *64*, 271–293.
- (19) Wang, Y.; Lan, D.; Durrani, R.; Hollmann, F. Peroxygenases en route to becoming dream catalysts. What are the opportunities and challenges? *Curr. Opin. Chem. Biol.* **2017**, *37*, 1–9.
- (20) Molina-Espeja, P.; Garcia-Ruiz, E.; Gonzalez-Perez, D.; Ullrich, R.; Hofrichter, M.; Alcalde, M. Directed evolution of unspecific peroxxygenase from *Agrocybe aegerita*. *Appl. Environ. Microbiol.* **2014**, *80*, 3496–3507.
- (21) Molina-Espeja, P.; Ma, S.; Mate, D. M.; Ludwig, R.; Alcalde, M. Tandem-yeast expression system for engineering and producing unspecific peroxxygenase. *Enzyme Microb. Technol.* **2015**, *73*–74, 29–33.
- (22) Otey, C. R.; Joern, J. M. High-throughput screen for aromatic hydroxylation. *Methods Mol. Biol.* **2003**, *230*, 141–148.
- (23) *Molecular Operating Environment (MOE)*, version 2010; Chemical Computing Group ULC: Canada, 2010.
- (24) Gonzalez-Perez, D.; Molina-Espeja, P.; Garcia-Ruiz, E.; Alcalde, M. Mutagenic Organized Recombination Process by Homologous IN vivo Grouping (MORPHING) for directed enzyme evolution. *PLoS One* **2014**, *9*, e90919.
- (25) Piontek, K.; Strittmatter, E.; Ullrich, R.; Gröbe, G.; Pecyna, M. J.; Kluge, M.; Scheibner, K.; Hofrichter, M.; Plattner, D. A. Structural Basis of Substrate Conversion in a New Aromatic Peroxygenase. Cytochrome P450 functionality with benefits. *J. Biol. Chem.* **2013**, *288*, 34767–34776.
- (26) Madadkar-Sobhani, A.; Guallar, V. PELE web server: atomistic study of biomolecular systems at your fingertips. *Nucleic Acids Res.* **2013**, *41*, W322–W328.
- (27) Schmidtke, P.; Bidon-Chanal, A.; Luque, F. J.; Barril, X. MDpocket: open-source cavity detection and characterization on molecular dynamics trajectories. *Bioinformatics* **2011**, *27*, 3276–3285.
- (28) Ni, Y.; Fernandez-Fueyo, E.; Gomez-Baraibar, A.; Ullrich, R.; Hofrichter, M.; Yanase, H.; Alcalde, M.; van Berkel, W. J. H.; Hollman, F. Peroxygenase-Catalyzed Oxyfunctionalization Reactions Promoted by the Complete Oxidation of Methanol. *Angew. Chem., Int. Ed.* **2016**, *55*, 798–801.
- (29) Bormann, S.; Gomez-Baraibar, A.; Ni, Y.; Holtmann, D.; Hollmann, F. Specific oxyfunctionalisations catalysed by peroxxygenases: opportunities, challenges and solutions. *Catal. Sci. Technol.* **2015**, *5*, 2038–2052.
- (30) Hofrichter, M.; Kellner, H.; Pecyna, M. J.; Ullrich, R. Fungal Unspecific Peroxygenases: Heme-Thiolate Proteins That Combine Peroxidase and Cytochrome P450 Properties. In *Monooxygenase, Peroxidase and Peroxygenase Properties and Mechanisms of Cytochrome P450*; Hryciay, E. G.; Bandiera, S. M., Eds.; Advances in Experimental Medicine and Biology; Springer International Publishing: Basel, Switzerland, 2015; Vol. 851, pp 341–368.
- (31) Molina-Espeja, P.; Gomez de Santos, P.; Alcalde, M. In *Directed evolution of unspecific peroxxygenase In: Directed Enzyme Evolution: Advances and Applications*; Alcalde, M., Ed.; Springer International Publishing: Basel, Switzerland, 2017; pp 127–143.
- (32) Gomez de Santos, P.; Molina-Espeja, P.; Plou, F. J.; Alcalde, M. Regioselective synthesis of 5'-hydroxypropranolol by aromatic peroxxygenase designed by directed evolution. Patent no. P300212672.
- (33) Alcalde, M. Mutagenesis Protocols in *Saccharomyces cerevisiae*. In *Vivo Overlap Extension In: In vitro Mutagenesis Protocols*, 3rd ed. *Methods in Molecular Biology*; Bramman, J., Ed.; Springer-Humana Press: New York, 2010; pp 3–15.
- (34) Kille, S.; Acevedo-Rocha, C. G.; Parra, L. P.; Zhang, Z. G.; Opperman, D. J.; Reetz, M. T.; Acevedo, J. P. Reducing codon redundancy and screening effort of combinatorial protein libraries created by saturation mutagenesis. *ACS Synth. Biol.* **2013**, *2*, 83–92.
- (35) Sastry, G. M.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. *J. Comput.-Aided Mol. Des.* **2013**, *27*, 221–234.
- (36) Anandakrishnan, R.; Aguilar, B.; Onufriev, A. V. H++ 3.0: automating pK prediction and the preparation of biomolecular



structures for atomistic molecular modeling and simulations. *Nucleic Acids Res.* **2012**, *40*, W537–W541.

(37) *Desmond Molecular Dynamics System*, version 2.2; D.E. Shaw Research, New York, NY, 2009. *Maestro-Desmond Interoperability Tools*, version 2.2; Schrödinger: New York.

(38) *QSite*, version 5.7; Schrödinger, LLC: New York, 2011.

(39) *Jaguar*, version 8.1; Schrödinger, LLC: New York, 2013.